Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The critters are restless and angry

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Feb 17, 2021 8:46pm

159 Views

Post# 32592176

RE:RE:The critters are restless and angry

Bvukmanic wrote: I blame Robert.

.. the company is making major changes .. lots of news on the way ... TSE asked to see more documents last week ... see the spike last week in the US? It really might be worth the wait!

Let's not be so quick to blame Robert

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China